ISRG Stock Analysis — Intuitive Surgical
Sector: Medical Devices
AI Verdict
ISRG trades at a premium that only makes sense if its robotic surgery moat keeps competitors at bay and the 37.9% earnings growth materializes.
Competitive Moat
Intuitive Surgical dominates robotic-assisted surgery with its da Vinci platform, which is protected by a vast installed base and deep surgeon training integration. The high switching costs and regulatory hurdles create a durable moat against new entrants.
Summary
The da Vinci robotic surgery system remains the gold standard for minimally invasive procedures, anchoring ISRG’s market power.
Where It Stands
ISRG is down -21.40% over the past year, trades at 36.5x next year’s earnings versus a healthcare sector median of 22x, and its RSI of 58.1 signals neutral momentum.
Key Metrics
- RSI: 58.1 — Neutral
- Trailing P/E: 50.4x
- Forward P/E: 36.5x
- PEG Ratio: 1.24
- Earnings Growth: +0.4%
- Revenue Growth: +0.2%
- Market Cap: $147.0B
- 1-Year Return: -21.40%
- 52-Week High: $603.88
- 52-Week Low: $396.68
Analyst Consensus
28 Buy · 11 Hold · 1 Sell (40 analysts)
Bull Case
With analysts forecasting 37.9% EPS growth and a forward P/E of 36.5x, you’re paying a fair price for high expected growth if da Vinci’s dominance holds.
Bear Case
If the forward P/E reverts to the sector median of 22x, the stock could see a further 40% downside even if earnings meet expectations.
Catalyst to Watch
Watch for FDA approvals or hospital adoption rates for new da Vinci models — either could accelerate or stall the expected earnings ramp.